UBS O'Connor’s Aerie Pharmaceuticals AERI Stock Holding History

UBS O'Connor’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,181	Closed	-$1.59M	–	468
2017 Q2	$1.59M	Buy	+30,181	New	+$1.41M	0.03%	278

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS O'Connor's AERI Position: Q3 2017 in Review

UBS O'Connor sold out of Aerie Pharmaceuticals (AERI) in Q3 2017, closing a stake of 30,181 shares — an estimated $1.59M sold.

UBS O'Connor first reported a position in AERI in Q2 2017 and held it in 1 quarter. The position peaked at $1.59M in Q2 2017. 182 funds tracked by Wall St. Rank hold AERI as of Q3 2017.

UBS O'Connor reported no remaining Aerie Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
UBS O'Connor sold 30,181 Aerie Pharmaceuticals shares in Q3 2017, an estimated $1.59M.
UBS O'Connor first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 1 quarter.
UBS O'Connor's Aerie Pharmaceuticals position peaked at $1.59M in Q2 2017.
182 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2017.

Based on UBS O'Connor's 13F filing for Q3 2017, filed 14 Nov 2017.